[go: up one dir, main page]

PE20230309A1 - Agentes quimioterapeuticos de eteres macrociclicos heteroaromaticos - Google Patents

Agentes quimioterapeuticos de eteres macrociclicos heteroaromaticos

Info

Publication number
PE20230309A1
PE20230309A1 PE2022002553A PE2022002553A PE20230309A1 PE 20230309 A1 PE20230309 A1 PE 20230309A1 PE 2022002553 A PE2022002553 A PE 2022002553A PE 2022002553 A PE2022002553 A PE 2022002553A PE 20230309 A1 PE20230309 A1 PE 20230309A1
Authority
PE
Peru
Prior art keywords
heteroaromatic
chemotherapy agents
macrocyclic ether
compounds
oxa
Prior art date
Application number
PE2022002553A
Other languages
English (en)
Inventor
Joshua Courtney Horan
Scot Richard Mente
Henry Efrem Pelish
Matthew D Shair
Xinxing Tang
Anupong Tangpeerachaikul
Original Assignee
Nuvalent Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvalent Inc filed Critical Nuvalent Inc
Publication of PE20230309A1 publication Critical patent/PE20230309A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS ETERES MACROCICLICOS HETEROAROMATICOS DE FORMULA (I) DONDE Q, X, Y, Z, R1 Y R4 SON TAL COMO SE DESCRIBEN EN EL PRESENTE DOCUMENTO. SON COMPUESTOS PREFERIDOS: (20R)-3-ETIL-17-FLUORO-20-METIL-21-OXA-3,4,12,24- TETRAAZAPENTACICLO[20.3.1.0 2,6.0 8,13.0 14,19]HEXACOSA-1(25),2(6),4,8(13),9,11,14,16,18,22(26),23-UNDECAENO-23-AMINA; (19R)-11-ETIL-16-FLUORO-3,19-DIMETIL-20-OXA-3,4,10,11,23-PENTAAZAPENTACICLO[19.3.1.0 2,6.0 8,12.0 13,18]PENTACOSA-1(24),2(6),4,8(12),9,13,15,17,21(25),22-DECAENO-22-AMINA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LOS PROTOONCOGENES ROS1 y ALK SIENDO UTILES EN EL TRATAMIENTO DE CANCER.
PE2022002553A 2020-05-05 2021-05-05 Agentes quimioterapeuticos de eteres macrociclicos heteroaromaticos PE20230309A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/088589 2020-05-05
US202063060331P 2020-08-03 2020-08-03
US202063125747P 2020-12-15 2020-12-15
PCT/US2021/030940 WO2021226269A1 (en) 2020-05-05 2021-05-05 Heteroaromatic macrocyclic ether chemotherapeutic agents

Publications (1)

Publication Number Publication Date
PE20230309A1 true PE20230309A1 (es) 2023-02-14

Family

ID=78468373

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022002553A PE20230309A1 (es) 2020-05-05 2021-05-05 Agentes quimioterapeuticos de eteres macrociclicos heteroaromaticos

Country Status (13)

Country Link
US (3) US11667649B2 (es)
EP (1) EP4146205A4 (es)
JP (2) JP7519464B2 (es)
KR (2) KR20240131463A (es)
AU (1) AU2021268345A1 (es)
BR (1) BR112022022530A2 (es)
CA (1) CA3179702A1 (es)
CL (1) CL2022003046A1 (es)
IL (1) IL297898A (es)
MX (1) MX2022013051A (es)
PE (1) PE20230309A1 (es)
PH (1) PH12022552787A1 (es)
WO (1) WO2021226269A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021226269A1 (en) 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
MX2022013657A (es) 2020-05-05 2023-02-01 Nuvalent Inc Quimioterápicos de éter macrocíclico heteroaromático.
MX2023012060A (es) 2021-04-13 2024-01-22 Nuvalent Inc Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr.
EP4408844A1 (en) 2021-10-01 2024-08-07 Nuvalent, Inc. Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
WO2023179600A1 (zh) * 2022-03-21 2023-09-28 杭州德睿智药科技有限公司 新型取代大杂环类新化合物及其应用
WO2023196900A1 (en) * 2022-04-07 2023-10-12 Nuvalent, Inc. Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
AU2023249645A1 (en) 2022-04-07 2024-10-03 Nuvalent, Inc Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine
CN115057877A (zh) * 2022-07-01 2022-09-16 苏州中科新药篮生物医药科技有限公司 一种克立硼罗的制备方法
KR20250099113A (ko) 2022-09-09 2025-07-01 이노보 테라퓨틱스 인코포레이티드 CK1α 및 DUAL CK1α/GSPT1 분해 화합물
WO2024074414A1 (en) * 2022-10-06 2024-04-11 Syngenta Crop Protection Ag Herbicidal imidazole compounds
WO2024086634A1 (en) * 2022-10-19 2024-04-25 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
WO2024046512A2 (zh) * 2022-12-01 2024-03-07 中国医药研究开发中心有限公司 含氮大环类化合物及其制备方法和医药用途
GB202311472D0 (en) * 2023-07-26 2023-09-06 Syngenta Crop Protection Ag Improvements in or relating to organic compounds
WO2025072117A1 (en) 2023-09-25 2025-04-03 Nuvalent, Inc. Heteroaromatic macrocyclic ether compounds and isotopologues thereof
WO2025072120A1 (en) * 2023-09-25 2025-04-03 Nuvalent, Inc. Heteroaromatic macrocyclic ether compounds
CN119264053A (zh) * 2024-09-29 2025-01-07 上海凌凯科技股份有限公司 一类吡唑衍生物的制备方法

Family Cites Families (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1020806A (en) 1911-03-25 1912-03-19 Walter J Devine Churn.
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
JPS60243083A (ja) 1984-05-18 1985-12-03 Nissan Chem Ind Ltd ピラゾ−ルスルホニルウレア誘導体、その製法および該誘導体を含有する除草剤
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5569655A (en) 1993-09-14 1996-10-29 Sterling Winthrop Inc. Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof
TW401301B (en) 1994-10-07 2000-08-11 Takeda Chemical Industries Ltd Antihypertriglyceridemic composition
AR002459A1 (es) 1995-01-17 1998-03-25 American Cyanamid Co Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
US5849735A (en) 1995-01-17 1998-12-15 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
WO1999006023A1 (en) 1997-07-29 1999-02-11 Alcon Laboratories, Inc. Ophthalmic compositions containing galactomannan polymers and borate
CA2318920A1 (en) 1998-01-29 1999-08-05 James W. Young Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
KR100766474B1 (ko) 2000-12-20 2007-10-15 교와 핫꼬 케미칼 가부시키가이샤 금속착체형 스쿠아리리움 화합물 및 이를 이용한 광기록매체
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
EP2325226A1 (en) 2002-10-30 2011-05-25 Sumitomo Chemical Company, Limited Complex aryl copolymer compounds and polymer light emitting devices made by using the same
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
ATE444732T1 (de) 2003-08-07 2009-10-15 Allergan Inc Zusammensetzungen zur abgabe von therapeutika in die augen und verfahren zu ihrer herstellung und verwendung
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2005104711A2 (en) 2004-04-27 2005-11-10 Wyeth Purification of progesterone receptor modulators
PA8631101A1 (es) 2004-04-27 2006-09-08 Wyeth Corp Proceso de acoplamiento para la generacion de derivados reactivos de pirrol-2-carbonitrilo n-sustituidos con contenido de boro para producir biarilos
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
AU2005287038B2 (en) 2004-09-20 2012-02-02 Janssen Pharmaceutica N.V. Novel tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators
US7445211B1 (en) 2005-03-11 2008-11-04 Walton Daniel J Wall decoration and game apparatus
US20070116984A1 (en) 2005-09-21 2007-05-24 Doosan Corporation Spiro-compound for electroluminescent display device and electroluminescent display device comprising the same
US20090022694A1 (en) 2005-10-18 2009-01-22 Distefano Peter Sirt1 inhibition
GB0526044D0 (en) 2005-12-21 2006-02-01 Syngenta Ltd Novel herbicides
EP2719388B1 (en) 2006-02-16 2019-04-10 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
GB0603891D0 (en) 2006-02-27 2006-04-05 Syngenta Ltd Novel herbicides
US20070213526A1 (en) 2006-03-07 2007-09-13 Wyeth Purification of progesterone receptor modulators
GB0609492D0 (en) * 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
US7915414B2 (en) 2006-11-24 2011-03-29 Yun Chi Blue-emitting organometallic complexes and their application
FR2913882B1 (fr) 2007-03-20 2009-05-01 Oreal Utilisation pour la coloration des fibres keratiniques d'une composition comprenant un compose halochromique et/ou le colorant correspondant a ce compose
ATE538120T1 (de) 2007-06-26 2012-01-15 Sanofi Sa Regioselektive, metallkatalysierte synthese annelierter benzimidazole und azabenzimidazole
RU2010103101A (ru) 2007-07-02 2011-08-10 Астразенека Аб (Se) Химические соединения
US10189803B2 (en) 2008-02-22 2019-01-29 Illinois Institute Of Technology Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
US9446995B2 (en) 2012-05-21 2016-09-20 Illinois Institute Of Technology Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
RU2015109165A (ru) 2008-03-06 2015-11-10 Анакор Фармасьютикалз, Инк. Борсодержащие малые молекулы в качестве противовоспалительных агентов
JP2009234928A (ja) 2008-03-25 2009-10-15 Kyoto Univ 縮合多環芳香族化合物、およびその製造方法
JP5304010B2 (ja) 2008-04-23 2013-10-02 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、表示装置及び照明装置
JP5499519B2 (ja) 2009-05-27 2014-05-21 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、表示装置及び照明装置
AU2010279907B2 (en) 2009-08-04 2013-10-10 Tokuyama Corporation Chromene compound
JP4599469B1 (ja) 2009-08-31 2010-12-15 富士フイルム株式会社 有機電界発光素子用材料及び有機電界発光素子
US8410091B1 (en) 2009-09-11 2013-04-02 Boehringer Ingelheim International Gmbh Process for preparation of substituted 2-amino-5-(5-(heterocyclemethyl)pyridin-2-yloxy)benzoic acid
CN102647904A (zh) 2009-09-16 2012-08-22 赛林药物股份有限公司 新型三环蛋白激酶调节剂
JP2013525476A (ja) 2010-05-04 2013-06-20 ファイザー・インク Ａｌｋ阻害剤としての複素環式誘導体
WO2012016147A2 (en) 2010-07-30 2012-02-02 Dr. Reddy's Laboratories Ltd. Ligands for selective asymmetric hydroformylation
US20120157448A1 (en) 2010-11-22 2012-06-21 Adam Cook Compounds for treating neurodegenerative diseases
CN103228660A (zh) 2010-12-01 2013-07-31 辉瑞大药厂 Kat ii 抑制剂
DK2655344T3 (da) 2010-12-22 2016-02-01 Univ Catholique Louvain Hidtil ukendte phenazin-derivater og deres anvendelse
FR2969611B1 (fr) 2010-12-28 2013-02-08 Sanofi Aventis Nouveaux derives de thiazoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
HUE030393T2 (en) 2010-12-28 2017-05-29 Sanofi Sa New pyrimidine derivatives, a process for their preparation, and their pharmaceutical use as inhibitors of AKT (PKB) phosphorylation
US20140030529A1 (en) 2011-01-27 2014-01-30 Tokuyama Corporation Chromene compound
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
EP2705039B1 (en) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
CN102408385B (zh) 2011-06-20 2014-06-18 雅本化学股份有限公司 一种2-取代-2h-1,2,3-三氮唑衍生物的制备方法
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
TWI506030B (zh) 2011-09-06 2015-11-01 Nat Univ Tsing Hua 含有碳烯配位基的過渡金屬錯合物結構及其在發光材料的應用
WO2013125543A1 (ja) 2012-02-20 2013-08-29 武田薬品工業株式会社 複素環化合物
CN102603659B (zh) 2012-03-01 2014-03-26 雅本化学股份有限公司 1-取代-4-溴-1h-1,2,3-三氮唑-5-羧酸及其制备方法
BR112014022106B1 (pt) 2012-03-06 2022-08-02 Pfizer Inc Derivados macrocíclicos, combinação, composição e usos na fabricação de um medicamento para o tratamento de doenças
KR20140032823A (ko) 2012-09-07 2014-03-17 롬엔드하스전자재료코리아유한회사 유기 전계 발광 소자
US9502667B2 (en) 2013-01-24 2016-11-22 Idemitsu Kosan Co., Ltd. Organic electroluminescence
WO2014138912A1 (en) 2013-03-13 2014-09-18 Queen's University At Kingston Luminescent compounds and methods of using same
US9637500B2 (en) 2013-06-28 2017-05-02 Pfizer Inc. Solid forms of a macrocyclic kinase inhibitor
ES2792979T3 (es) 2013-08-22 2020-11-12 Jubilant Biosys Ltd Compuestos de pirimidina sustituidos, composiciones y aplicaciones médicas de los mismos
KR102100929B1 (ko) 2013-09-04 2020-04-14 삼성전자주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
HUE053645T2 (hu) 2013-11-18 2021-07-28 Forma Therapeutics Inc Tetrahidrokinolin kompozíciók mint BET bromodomén inhibitorok
US20160256448A1 (en) 2013-11-18 2016-09-08 Forma Therapeutics, Inc. Tetrahydroquinoline compositions as bet bromodomain inhibitors
ES2906062T3 (es) 2013-11-29 2022-04-13 Proionic Gmbh Procedimiento para la unión de un material termoplástico por medio de radiación de microondas
KR102167048B1 (ko) 2013-12-03 2020-10-19 삼성디스플레이 주식회사 화합물 및 이를 포함한 유기 발광 소자
WO2015100268A1 (en) 2013-12-23 2015-07-02 The Regents Of The University Of California Mesenchymal stem cells for targeted cancer therapy
CA2935903A1 (en) 2014-01-09 2015-07-16 Hadasit Medical Research Services And Development Ltd. Improved cell compositions and methods for cancer therapy
KR102191992B1 (ko) 2014-01-22 2020-12-17 삼성디스플레이 주식회사 유기 발광 소자
KR102253441B1 (ko) 2014-03-10 2021-05-20 삼성디스플레이 주식회사 화합물 및 이를 포함한 유기 발광 소자
CN105130966B (zh) 2014-05-07 2019-05-24 广东东阳光药业有限公司 炔基化合物及其使用方法和用途
WO2015175579A1 (en) 2014-05-15 2015-11-19 Calitor Sciences, Llc Alkynyl compounds and methods of use
WO2016026423A1 (en) * 2014-08-20 2016-02-25 Teligene Ltd Substituted macrocycles useful as kinases inhibitors and methods of use thereof
KR101793335B1 (ko) 2014-09-30 2017-11-02 주식회사 엘지화학 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자
CN105585534B (zh) 2014-10-23 2018-05-18 上海雅本化学有限公司 一种1-取代-1h-1,2,3-三氮唑-4-羧酸的制备方法
US20160140491A1 (en) 2014-11-17 2016-05-19 Gregory Forgatch System and method for integrating intermediary and end-user online retail experiences
CN107207472B (zh) 2014-12-23 2020-08-14 卑尔根生物股份公司 Akt激酶的抑制剂
US9776443B1 (en) 2015-01-13 2017-10-03 My Sweet Petunia, Inc. Craftwork tools and kits
PH12017501279B1 (en) 2015-01-22 2023-06-16 Myokardia Inc 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
US9887372B2 (en) 2015-06-11 2018-02-06 Samsung Display Co., Ltd. Amine-based compound and organic light-emitting device including the same
JP6548976B2 (ja) 2015-06-30 2019-07-24 富士通株式会社 平面アンテナ
CA2994703A1 (en) 2015-08-03 2017-02-09 Bristol-Myers Squibb Company Cyclic compounds useful as modulators of tnf alpha
WO2017080980A1 (en) 2015-11-09 2017-05-18 Astrazeneca Ab Dihydropyrrolopyrazinone derivatives useful in the treatment of cancer
CN108834415B (zh) 2015-11-13 2021-12-24 多曼治疗学公司 作为ii组代谢型谷氨酸受体的别构调节剂的取代的三环1,4-苯并二氮杂䓬酮衍生物
ES2939977T3 (es) 2015-11-25 2023-04-28 Gilead Apollo Llc Inhibidores de triazol ACC y usos de los mismos
CN105669733A (zh) 2016-01-29 2016-06-15 上海毕路得医药科技有限公司 一种1-甲基-1h-吡唑-3-硼酸频哪醇酯的合成方法
JP6802850B2 (ja) 2016-03-03 2020-12-23 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ，Ｉｎｃ． 大環状化合物および該化合物を含む組成物
US10245064B2 (en) 2016-07-12 2019-04-02 Ethicon Llc Ultrasonic surgical instrument with piezoelectric central lumen transducer
US20180034646A1 (en) 2016-07-27 2018-02-01 Arris Enterprises Llc Method and apparatus for seamless remote renewal of offline generated digital identity certificates to field deployed hardware security modules
CN106243096B (zh) 2016-07-29 2019-11-29 上海璃道医药科技有限公司 三环类药物的新用途
JP6798851B2 (ja) 2016-10-14 2020-12-09 株式会社トクヤマ クロメン化合物、及び該クロメン化合物を含む硬化性組成物
CN110072859B (zh) 2016-12-13 2022-10-11 勃林格殷格翰国际有限公司 作为RORγ调节剂的化合物
TW201831340A (zh) 2017-02-22 2018-09-01 日商壽股份有限公司 筆具
CN109528717B (zh) 2017-09-21 2021-08-17 中国科学院分子细胞科学卓越创新中心 治疗或预防肥胖或其相关疾病的化合物及其应用
JOP20180092A1 (ar) 2017-10-13 2019-04-13 Gilead Sciences Inc مثبطات hiv بروتياز
WO2019113071A1 (en) 2017-12-05 2019-06-13 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating alk-mediated cancer
CN111315721B (zh) 2017-12-21 2023-06-06 广州华睿光电材料有限公司 有机混合物及其在有机电子器件中的应用
WO2019149131A1 (zh) * 2018-01-30 2019-08-08 上海吉倍生物技术有限公司 具有大环分子结构的化合物及其用途
MX2020008182A (es) 2018-02-11 2020-09-22 Jiangsu Hansoh Pharmaceutical Group Co Ltd Reguladores de derivados esteroides, metodo para prepararlos y usos de los mismos.
WO2019164301A1 (ko) 2018-02-21 2019-08-29 주식회사 엘지화학 화합물 및 이를 포함하는 유기 발광 소자
US10842811B2 (en) 2018-02-28 2020-11-24 The Trustees Of Columbia University In The City Of New York Inulin for preventing antibiotic resistant infection and pathogen colonization
KR102192368B1 (ko) 2018-02-28 2020-12-17 주식회사 엘지화학 유기 발광 소자
CN110357905B (zh) 2018-03-26 2021-10-01 武汉誉祥医药科技有限公司 作为蛋白激酶抑制剂的大环类衍生物及其制备方法和用途
CN108912175A (zh) 2018-06-05 2018-11-30 长春海谱润斯科技有限公司 一种金属铱配合物及其有机发光器件
US11560399B2 (en) 2018-07-26 2023-01-24 Enterome Process for preparing mannose derivatives
US10593889B1 (en) 2018-09-26 2020-03-17 Idemitsu Kosan Co., Ltd. Compound and organic electroluminescence device
CA3109686A1 (en) 2018-09-27 2020-04-02 Dana-Farber Cancer Institute, Inc. Degraders that target alk and therapeutic uses thereof
KR102163494B1 (ko) 2018-10-26 2020-10-08 한국과학기술연구원 단백질 키나아제 저해제인 헤테로방향족 매크로시클릭 유도체
WO2020092196A1 (en) 2018-10-30 2020-05-07 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alpha
CN109912433B (zh) 2019-03-07 2022-04-08 石家庄诚志永华显示材料有限公司 化合物、有机电致发光材料、有机电致发光器件、电子装置
KR20200111577A (ko) 2019-03-19 2020-09-29 삼성전자주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
KR20220004206A (ko) 2019-05-14 2022-01-11 텔리진 엘티디. 키네이스 억제제로 유용한 치환된 거대고리화합물
CN114207861B (zh) 2019-08-02 2024-11-15 德山新勒克斯有限公司 有机电子器件
CN112321604A (zh) 2019-08-05 2021-02-05 华东理工大学 大环类jak2抑制剂及其应用
GB201913756D0 (en) 2019-09-24 2019-11-06 Chromatwist Ltd Contrast agent
WO2021057882A1 (zh) 2019-09-26 2021-04-01 贝达药业股份有限公司 Egfr抑制剂、组合物及其制备方法
US20230027026A1 (en) 2019-09-27 2023-01-26 Jubilant Biosys Limited Fused pyrimidine compounds, compositions and medicinal applications thereof
CN110734456A (zh) 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
CA3158743A1 (en) 2019-11-15 2021-05-20 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
CN112812128B (zh) 2019-11-18 2024-04-02 正大天晴药业集团股份有限公司 作为alk和ros调节剂的大环化合物
NZ789851A (en) 2019-12-16 2025-08-29 I Sens Inc Novel transition metal electron transfer complex having c-n ligand and electrochemical bio sensor using same
TW202136246A (zh) 2019-12-19 2021-10-01 德商麥克專利有限公司 電子裝置用化合物
CN113121607B (zh) 2019-12-31 2023-07-04 马鞍山南大高新技术研究院有限公司 一种主配体含喹啉/喹唑啉的红光铱配合物与应用
BR112022019517A2 (pt) 2020-03-30 2022-12-06 Hutchison Medipharma Ltd Compostos de amida e usos dos mesmos
CN111440154B (zh) 2020-04-24 2022-04-19 梯尔希（南京）药物研发有限公司 一种替格列汀二聚体杂质的合成方法
CN111362967B (zh) 2020-04-28 2021-09-07 南京雷正医药科技有限公司 苯并氧杂二氮杂十四碳烯衍生物及其用途
MX2022013657A (es) 2020-05-05 2023-02-01 Nuvalent Inc Quimioterápicos de éter macrocíclico heteroaromático.
WO2021226269A1 (en) 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
US20230174551A1 (en) 2020-05-05 2023-06-08 Basf Se Condensed isoxazoline derivatives and their use as herbicides
US12454525B2 (en) 2020-05-06 2025-10-28 Merck Sharp & Dohme Llc IL4I1 inhibitors and methods of use
CN115996932B (zh) 2020-05-06 2025-08-01 法国施维雅药厂 新的大环lrrk2激酶抑制剂
TWI827924B (zh) 2020-05-06 2024-01-01 美商安進公司 大環Mcl-1抑制劑中間體的閉環合成
EP4146622A1 (en) 2020-05-06 2023-03-15 Amgen Inc. Synthesis of sulfonamide intermediates
EP4137495A4 (en) 2020-05-18 2023-09-20 Shenzhen TargetRx, Inc. SOLID FORM OF MACROCYCLIC COMPOUND, ITS PREPARATION AND USE
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
WO2022194399A1 (en) 2020-07-13 2022-09-22 Idorsia Pharmaceuticals Ltd Macrocycles as cftr modulators
CN115362155B (zh) 2020-07-22 2024-06-18 中国医药研究开发中心有限公司 芳胺类衍生物及其制备方法和医药用途
CN111808147B (zh) 2020-07-28 2023-04-18 奥来德(上海)光电材料科技有限公司 一种有机磷光材料及其制备方法和电致发光器件
CA3207819A1 (en) 2021-02-19 2022-08-25 Anjali Pandey Tyk2 inhibitors and uses thereof
US11814367B2 (en) 2021-03-15 2023-11-14 Maze Therapeutics, Inc. Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof
WO2022212538A1 (en) 2021-03-31 2022-10-06 Blueprint Medicines Corporation Diazepanone-fused pyrimidine compounds, compositions and medicinal applications thereof
CN113105440B (zh) 2021-04-15 2022-10-04 吉林奥来德光电材料股份有限公司 一种有机电致发光化合物及其制备方法和应用
US12503454B2 (en) 2021-05-13 2025-12-23 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
WO2022241171A1 (en) 2021-05-14 2022-11-17 Bristol-Myers Squibb Company Substituted heterocyclic compounds
EP4408844A1 (en) 2021-10-01 2024-08-07 Nuvalent, Inc. Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
US20240398768A1 (en) 2021-10-01 2024-12-05 Nuvalent, Inc. Methods of treating solid tumor using heteroaromatic macrocyclic ether compounds
WO2023059801A1 (en) 2021-10-06 2023-04-13 The Regents Of The University Of Colorado, A Body Corporate Biomarkers for egfr-mediated resistance in oncogene-driven cancers and methods of treating, preventing, and/or ameliorating oncogene-driven cancers
WO2023179600A1 (zh) 2022-03-21 2023-09-28 杭州德睿智药科技有限公司 新型取代大杂环类新化合物及其应用
WO2023196900A1 (en) 2022-04-07 2023-10-12 Nuvalent, Inc. Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
WO2024046512A2 (zh) 2022-12-01 2024-03-07 中国医药研究开发中心有限公司 含氮大环类化合物及其制备方法和医药用途

Also Published As

Publication number Publication date
BR112022022530A2 (pt) 2023-02-23
MX2022013051A (es) 2023-01-24
EP4146205A4 (en) 2024-05-29
KR102698413B1 (ko) 2024-08-26
WO2021226269A1 (en) 2021-11-11
US11667649B2 (en) 2023-06-06
EP4146205A1 (en) 2023-03-15
KR20240131463A (ko) 2024-08-30
CL2022003046A1 (es) 2023-10-06
US20250382304A1 (en) 2025-12-18
US20230076627A1 (en) 2023-03-09
AU2021268345A1 (en) 2022-11-10
US20220340586A9 (en) 2022-10-27
JP7519464B2 (ja) 2024-07-19
CA3179702A1 (en) 2021-11-11
JP2024133654A (ja) 2024-10-02
KR20230005987A (ko) 2023-01-10
US20220098212A1 (en) 2022-03-31
US12275742B2 (en) 2025-04-15
JP2023525040A (ja) 2023-06-14
IL297898A (en) 2023-01-01
PH12022552787A1 (en) 2024-03-25

Similar Documents

Publication Publication Date Title
PE20230309A1 (es) Agentes quimioterapeuticos de eteres macrociclicos heteroaromaticos
AR053412A1 (es) Compuestos inhibidores de la interaccion entre mdm2 y p53, un metodo de preparadcion, composicion farmaceutica y uso del compuesto para fabricar medicamentos
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
ECSP099803A (es) Derivados de bencimidazol
PE20090902A1 (es) Combinacion de un antimitotico e inhibidor de aurora quinasa como agentes anticancerigenos
UY30310A1 (es) Derivados 2-azetidinona, sales, solvatos, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
PE20091116A1 (es) Derivados de piridina y pirazina como inhibidores de tirosina quinasas
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
PA8593001A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
UY30789A1 (es) Derivados de adenina, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
UY31334A1 (es) 3a,4,5,6,7,7a-hexahidro-3h-benzoimidazol y derivaods de 3a, 4,5,6,,7,7a-hexahidro-3-indol, enantiómeros, diastereoisómeros, sales farmacéuticamente aceptadas, mezclas, composiciones, preparaciones y aplicaciones de las mismas
PE20220017A1 (es) Inhibidores del kcnt1 y metodos de uso
UY30393A1 (es) Derivados sustituidos de la 1-piperidin-1-il-1,3-dihidro-2h-benzimidazol-2-ona, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
UY30544A1 (es) Compuestos de pirrolo-piperidina y sales farmacéuticametne aceptables de los mismos, procesos de fabricacion, composiciones y aplicaciones
DOP2010000022A (es) Derivados de pirimidina 934
MX2022001161A (es) Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos.
UY30397A1 (es) Derivados sustituidos de la (3as, 7as)-1,3a,4,5,6,7-hexahidro-3h-benzoimidazol-2-ona, proceso de preparacion, composiciones conteniéndolos yaplicaciones
DOP2010000374A (es) Derivados heterociclicos de la urea y sus metodos de empleo
CO6382176A2 (es) Derivados de urea heterociclicos y metodos de uso de los mismos-332
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
PE20151782A1 (es) Derivados de azaquinolin-carboxamida
UY30363A1 (es) Derivados sustituidos de la n-(3-oxo-2,3-dihidro-1h-isoindol-4-il)-1-naftamida, procesos de preparacion, composiciones farmacéuticas y aplicaciones
UY29486A1 (es) Compuestos utiles en terapia
AR056369A1 (es) Compuestos derivados de quinazolina y composicion farmaceutica